Atlas Trials

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

Clinical trial NCT04530656 · COMPLETED

Trial details

NCT number
NCT04530656
Sponsor
Jiangsu Province Centers for Disease Control and Prevention
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19
Start date
2020-08-28
Primary completion
2020-10-28
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.